Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
MYRIAD GENETICS INC (MYGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/07/2020 8-K/A Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Total Second-Quarter Revenues of $195.1 Million • Second-Quarter Diluted EPS of and Adjusted EPS of $0.23 SALT LAKE CITY, Feb. 6, 2020 – Myriad Genetics, Inc. , a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal second-quarter 2020, provided an update on recent business highlights and provided revised fiscal year and third-quarter 2020 financial guidance. "Revenue in the fiscal second quarter fell short of expectations largely due to the prenatal business. Prenatal cash collections were negatively impacted by issues in billing operations that occurred during the transition of the homegrown Counsyl billing system to an industry-standard system used by Myriad. We are in the process of implementing a number of initiatives f..."
10/12/2018 8-K/A Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "FORM 8-K/A",
"Consent of Independent Registered Public Accounting Firm for Counsyl, Inc",
"Audited Financial Statements of Counsyl, Inc. as of and for the year ended December 31, 2017",
"Unaudited consolidated financial statements of Counsyl, Inc. as of March 31, 2018 and for the three-month periods ended March 31, 2018 and 2017",
"Unaudited Pro Forma Condensed Combined Financial Statements of Myriad Genetics, Inc. and Subsidiaries"
11/14/2016 8-K/A Form 8-K/A - Current report [Amend]
05/09/2014 8-K/A Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "Consent of Independent Auditors for Crescendo Bioscience, Inc. (Ernst & Young LLP)",
"Audited Financial Statements of Crescendo Bioscience, Inc. as of and for the year ended December 31, 2013",
"Unaudited Pro Forma Combined Financial Statements of Myriad Genetics, Inc. and Subsidiaries"
02/06/2007 8-K/A Form 8-K/A - Current report [Amend]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy